We are live on ! Find out more
MRVI icon

Maravai LifeSciences

118 hedge funds and large institutions have $2.73B invested in Maravai LifeSciences in 2020 Q4 according to their latest regulatory filings, with 118 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

1,490% more call options, than puts

Call options by funds: $5.21M | Put options by funds: $328K

100.83% more ownership

Funds ownership: 0%100.83% (+101%)

Holders
118
Holders Change
+118
Holders Change %
% of All Funds
2.09%
Holding in Top 10
5
Holding in Top 10 Change
+5
Holding in Top 10 Change %
% of All Funds
0.09%
New
118
Increased
Reduced
Closed
Calls
$5.21M
Puts
$328K
Net Calls
+$4.89M
Net Calls Change
+$4.89M

MRVI Hedge Fund Activity: Q4 2020 in Review

118 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Maravai LifeSciences (MRVI) for Q4 2020, worth a combined $2.73B.

Buyers outnumbered sellers: 118 funds opened new MRVI positions and 0 closed out — a net gain of 118 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was D1 Capital Partners, opening a new position worth an estimated $165M.

  • 118 institutional investors held Maravai LifeSciences (MRVI) as of Q4 2020, up from 0 in Q3 2020.
  • Funds reported $2.73B of Maravai LifeSciences stock for Q4 2020.
  • 118 funds opened new Maravai LifeSciences positions in Q4 2020 and 0 closed out, a net change of +118 holders.
  • The largest Maravai LifeSciences buyer in Q4 2020 was D1 Capital Partners, an estimated $165M added.

Based on aggregated 13F filings for Q4 2020.